Literature DB >> 16750370

Periosteal autologous chondrocyte implantation for patellar chondral defect in patients with normal and abnormal patellar tracking.

I J P Henderson1, P Lavigne.   

Abstract

Reported results for patellar ACI include a mixed population of patients having or not a concomitant correction of the extensor mechanism. No study has reported separate outcome for those two patellar ACI subgroups. Forty four patients were included in this study designed to compare the outcome of patellar ACI with extensor realignment (group A) to patellar ACI with normal patellofemoral tracking (group B). Group A (n=22) had a higher increase in average modified Cincinnati knee score (4.5 vs. 1.7 points), better function (1.7 vs. 2.5), better SF-36 physical component scores (70.9 vs. 55.4 points) and higher IKDC scores (85.2 vs. 60.6 points) when compared to group B (n=22) at an average follow-up of 2 years. Patellar ACI with concomitant extensor realignment has superior outcome than patellar ACI with normal patellofemoral tracking. An unloading osteotomy could be desirable in selected patients with normal patellofemoral biomechanics to improve the outcome in this population.

Entities:  

Mesh:

Year:  2006        PMID: 16750370     DOI: 10.1016/j.knee.2006.04.006

Source DB:  PubMed          Journal:  Knee        ISSN: 0968-0160            Impact factor:   2.199


  29 in total

Review 1.  Surgical treatment for early osteoarthritis. Part I: cartilage repair procedures.

Authors:  A H Gomoll; G Filardo; L de Girolamo; J Espregueira-Mendes; J Esprequeira-Mendes; M Marcacci; W G Rodkey; J R Steadman; R J Steadman; S Zaffagnini; E Kon
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-11-24       Impact factor: 4.342

Review 2.  Surgical treatment for early osteoarthritis. Part II: allografts and concurrent procedures.

Authors:  A H Gomoll; G Filardo; F K Almqvist; W D Bugbee; M Jelic; J C Monllau; G Puddu; W G Rodkey; P Verdonk; R Verdonk; S Zaffagnini; M Marcacci
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-11-09       Impact factor: 4.342

Review 3.  Staging and comorbidities.

Authors:  Christian Lattermann; Matthew R Luckett
Journal:  J Knee Surg       Date:  2011-12       Impact factor: 2.757

Review 4.  [Patellofemoral arthroplasty: indication, technique and results].

Authors:  M Cotic; A B Imhoff
Journal:  Orthopade       Date:  2014-10       Impact factor: 1.087

Review 5.  Cartilage lesions in patellofemoral dislocations: incidents/locations/when to treat.

Authors:  Jack Farr; D Jeff Covell; Christian Lattermann
Journal:  Sports Med Arthrosc Rev       Date:  2012-09       Impact factor: 1.985

6.  Cell-based therapy improves function in adolescents and young adults with patellar osteochondritis dissecans.

Authors:  Bryon J X Teo; Kizher Buhary; Bee-Choo Tai; James H Hui
Journal:  Clin Orthop Relat Res       Date:  2013-04       Impact factor: 4.176

7.  Matrix-induced autologous chondrocyte implantation (MACI) for chondral defects in the patellofemoral joint.

Authors:  Daniel Meyerkort; Jay R Ebert; Timothy R Ackland; William B Robertson; Michael Fallon; M H Zheng; David J Wood
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-05-11       Impact factor: 4.342

Review 8.  Biomechanical outcomes of cartilage repair of the knee.

Authors:  Carmen E Quatman; Joshua D Harris; Timothy E Hewett
Journal:  J Knee Surg       Date:  2012-07       Impact factor: 2.757

9.  Patient-oriented and performance-based outcomes after knee autologous chondrocyte implantation: a timeline for the first year of recovery.

Authors:  Jennifer S Howard; Carl G Mattacola; David R Mullineaux; Robert A English; Christian Lattermann
Journal:  J Sport Rehabil       Date:  2014-02-28       Impact factor: 1.931

10.  Clinical outcome after medial patellofemoral ligament reconstruction and autologous chondrocyte implantation following recurrent patella dislocation.

Authors:  Rainer Siebold; Georgios Karidakis; Francis Fernandez
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-08-01       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.